Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Роль цефалоспоринов III поколения в терапии инфекционных заболеваний верхних дыхательных путей и уха
Роль цефалоспоринов III поколения в терапии инфекционных заболеваний верхних дыхательных путей и уха
Мальцева Г.С. Роль цефалоспоринов III поколения в терапии инфекционных заболеваний верхних дыхательных путей и уха. Consilium Medicum. Болезни органов дыхания (Прил.). 2015; с. 26–30.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Основными бактериальными патогенами, обусловливающими развитие острого синусита и острого среднего отита, являются Streptococcus pneumoniae, Hemophilus influenzaе и Moraxella catarrhalis. До недавнего времени наибольшую опасность представляла S. pneumoniaе, и антибактериальная терапия была ориентирована главным образом на борьбу с этим микроорганизмом. Однако внесение вакцинации против пневмококка в обязательный календарь прививок в России приведет (как сложилось уже в США и Западной Европе) к изменению микробного пейзажа при заболеваниях верхних дыхательных путей и уха. Вместо пневмококка лидирующее место займет гемофильная палочка (H. influenzae). Эти изменения микробного пейзажа должны учитываться при выборе адекватной антибактериальной терапии. В статье приводится обзор данных клинических исследований эффективности и безопасности цефиксима при заболеваниях верхних дыхательных путей и уха.
Ключевые слова: острый средний отит, острый синусит, Streptococcus pneumoniae, Hemophilus influenzae и Moraxella catarrhalis, антибиотикотерапия.
Key words: acute otitis media, acute sinusitis, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, antibiotic therapy.
Ключевые слова: острый средний отит, острый синусит, Streptococcus pneumoniae, Hemophilus influenzae и Moraxella catarrhalis, антибиотикотерапия.
________________________________________________
Key words: acute otitis media, acute sinusitis, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, antibiotic therapy.
Полный текст
Список литературы
1. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002; 161: 188–95.
2. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. Клин. микробиология и антимикробная химиотерапия. 2010; 4: 1–13. / Kozlov R.S., Sivaia O.V., Krechikova O.I. i dr. Dinamika rezistentnosti Streptococcus pneumoniae k antibiotikam v Rossii za period 1999–2009 gg. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 4: 1–13. [in Russian]
3. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
4. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354 (14): 1455–63.
5. Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther 2006; 28 (1): 118–23.
6. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis 2004; 23 (9): 829–33.
7. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis 2007; 26 (2): 123–8.
8. Harrison CJ, Woods C, Strout G et al. Susceptibilities of Haemophilus influenza, Streptococcus pneumonia, including serotype 19A, and Moraxella catarrhalis peadiatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63 (3): 511–9.
9. Jansen WTM, Verel A, Beitsma M et al. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenza. J Antimicrob Chemother 2006; 58: 873–7.
10. Hausen Th, Weidlich G, Schmitt J. Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection 1995; 23 (Suppl. 2): 65–9.
11. Wu DH. Efficacy and tolerability of cefixime in otitis media. Drugs 1991; 42 (Suppl. 4): 30–2.
12. McLinn SE. Randomized, open label,multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 997–1001.
13. Owen MJ, Anwar R, Nguyen HK et al. Efficacy of cefixime in the treatment of acute otitis media in children. Am J Dis Child 1993; 147: 81–6.
14. Johnson CE, Carlin SA, Super DM et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22.
15. Rodriguez WJ, Khan W, Sait T et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: A randomized, comparative study. Pediatr Infect Dis J 1993; 12: 70–4.
16. Gooch WM III, Philips A, Rhoades R et al. Comparison of the efficacy,safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 1997; 16 (Suppl. 2): 21–4.
17. Sunderland R, Mcvey DL, Atkin KJ. Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. Curr Ther Res 1994; 55 (Suppl. A): 22–9.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310.
19. Фомина И.П., Смирнова Л.Б. Современное значение орального цефалоспорина III поколения цефиксима в терапии бактериальных инфекций. Инфекции и антимикробная терапия. 2012; 4 (3): 38–40. / Fomina I.P., Smirnova L.B. Sovremennoe znachenie oral'nogo tsefalosporina III pokoleniia tsefiksima v terapii bakterial'nykh infektsii. Infektsii i antimikrobnaia terapiia. 2012; 4 (3): 38–40. [in Russian]
20. Brogden RN, Campoli Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50.
2. Kozlov R.S., Sivaia O.V., Krechikova O.I. i dr. Dinamika rezistentnosti Streptococcus pneumoniae k antibiotikam v Rossii za period 1999–2009 gg. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 4: 1–13. [in Russian]
3. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
4. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354 (14): 1455–63.
5. Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther 2006; 28 (1): 118–23.
6. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis 2004; 23 (9): 829–33.
7. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis 2007; 26 (2): 123–8.
8. Harrison CJ, Woods C, Strout G et al. Susceptibilities of Haemophilus influenza, Streptococcus pneumonia, including serotype 19A, and Moraxella catarrhalis peadiatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63 (3): 511–9.
9. Jansen WTM, Verel A, Beitsma M et al. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenza. J Antimicrob Chemother 2006; 58: 873–7.
10. Hausen Th, Weidlich G, Schmitt J. Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection 1995; 23 (Suppl. 2): 65–9.
11. Wu DH. Efficacy and tolerability of cefixime in otitis media. Drugs 1991; 42 (Suppl. 4): 30–2.
12. McLinn SE. Randomized, open label,multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 997–1001.
13. Owen MJ, Anwar R, Nguyen HK et al. Efficacy of cefixime in the treatment of acute otitis media in children. Am J Dis Child 1993; 147: 81–6.
14. Johnson CE, Carlin SA, Super DM et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22.
15. Rodriguez WJ, Khan W, Sait T et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: A randomized, comparative study. Pediatr Infect Dis J 1993; 12: 70–4.
16. Gooch WM III, Philips A, Rhoades R et al. Comparison of the efficacy,safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 1997; 16 (Suppl. 2): 21–4.
17. Sunderland R, Mcvey DL, Atkin KJ. Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. Curr Ther Res 1994; 55 (Suppl. A): 22–9.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310.
19. Fomina I.P., Smirnova L.B. Sovremennoe znachenie oral'nogo tsefalosporina III pokoleniia tsefiksima v terapii bakterial'nykh infektsii. Infektsii i antimikrobnaia terapiia. 2012; 4 (3): 38–40. [in Russian]
20. Brogden RN, Campoli Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50.
2. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. Клин. микробиология и антимикробная химиотерапия. 2010; 4: 1–13. / Kozlov R.S., Sivaia O.V., Krechikova O.I. i dr. Dinamika rezistentnosti Streptococcus pneumoniae k antibiotikam v Rossii za period 1999–2009 gg. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 4: 1–13. [in Russian]
3. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
4. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354 (14): 1455–63.
5. Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther 2006; 28 (1): 118–23.
6. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis 2004; 23 (9): 829–33.
7. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis 2007; 26 (2): 123–8.
8. Harrison CJ, Woods C, Strout G et al. Susceptibilities of Haemophilus influenza, Streptococcus pneumonia, including serotype 19A, and Moraxella catarrhalis peadiatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63 (3): 511–9.
9. Jansen WTM, Verel A, Beitsma M et al. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenza. J Antimicrob Chemother 2006; 58: 873–7.
10. Hausen Th, Weidlich G, Schmitt J. Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection 1995; 23 (Suppl. 2): 65–9.
11. Wu DH. Efficacy and tolerability of cefixime in otitis media. Drugs 1991; 42 (Suppl. 4): 30–2.
12. McLinn SE. Randomized, open label,multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 997–1001.
13. Owen MJ, Anwar R, Nguyen HK et al. Efficacy of cefixime in the treatment of acute otitis media in children. Am J Dis Child 1993; 147: 81–6.
14. Johnson CE, Carlin SA, Super DM et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22.
15. Rodriguez WJ, Khan W, Sait T et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: A randomized, comparative study. Pediatr Infect Dis J 1993; 12: 70–4.
16. Gooch WM III, Philips A, Rhoades R et al. Comparison of the efficacy,safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 1997; 16 (Suppl. 2): 21–4.
17. Sunderland R, Mcvey DL, Atkin KJ. Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. Curr Ther Res 1994; 55 (Suppl. A): 22–9.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310.
19. Фомина И.П., Смирнова Л.Б. Современное значение орального цефалоспорина III поколения цефиксима в терапии бактериальных инфекций. Инфекции и антимикробная терапия. 2012; 4 (3): 38–40. / Fomina I.P., Smirnova L.B. Sovremennoe znachenie oral'nogo tsefalosporina III pokoleniia tsefiksima v terapii bakterial'nykh infektsii. Infektsii i antimikrobnaia terapiia. 2012; 4 (3): 38–40. [in Russian]
20. Brogden RN, Campoli Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50.
________________________________________________
2. Kozlov R.S., Sivaia O.V., Krechikova O.I. i dr. Dinamika rezistentnosti Streptococcus pneumoniae k antibiotikam v Rossii za period 1999–2009 gg. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2010; 4: 1–13. [in Russian]
3. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229–46.
4. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354 (14): 1455–63.
5. Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther 2006; 28 (1): 118–23.
6. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis 2004; 23 (9): 829–33.
7. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis 2007; 26 (2): 123–8.
8. Harrison CJ, Woods C, Strout G et al. Susceptibilities of Haemophilus influenza, Streptococcus pneumonia, including serotype 19A, and Moraxella catarrhalis peadiatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63 (3): 511–9.
9. Jansen WTM, Verel A, Beitsma M et al. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenza. J Antimicrob Chemother 2006; 58: 873–7.
10. Hausen Th, Weidlich G, Schmitt J. Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection 1995; 23 (Suppl. 2): 65–9.
11. Wu DH. Efficacy and tolerability of cefixime in otitis media. Drugs 1991; 42 (Suppl. 4): 30–2.
12. McLinn SE. Randomized, open label,multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J 1987; 6: 997–1001.
13. Owen MJ, Anwar R, Nguyen HK et al. Efficacy of cefixime in the treatment of acute otitis media in children. Am J Dis Child 1993; 147: 81–6.
14. Johnson CE, Carlin SA, Super DM et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22.
15. Rodriguez WJ, Khan W, Sait T et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: A randomized, comparative study. Pediatr Infect Dis J 1993; 12: 70–4.
16. Gooch WM III, Philips A, Rhoades R et al. Comparison of the efficacy,safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 1997; 16 (Suppl. 2): 21–4.
17. Sunderland R, Mcvey DL, Atkin KJ. Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. Curr Ther Res 1994; 55 (Suppl. A): 22–9.
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310.
19. Fomina I.P., Smirnova L.B. Sovremennoe znachenie oral'nogo tsefalosporina III pokoleniia tsefiksima v terapii bakterial'nykh infektsii. Infektsii i antimikrobnaia terapiia. 2012; 4 (3): 38–40. [in Russian]
20. Brogden RN, Campoli Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50.
Авторы
Г.С.Мальцева*
ФГБУ Санкт-Петербургский НИИ уха, горла, носа и речи Минздрава России. 190013, Россия, Санкт-Петербург, ул. Бронницкая, д. 9
*g.s.maltseva@gmail.com
Saint Petersburg Institute of ear, nose and throat and speech of the Ministry of Health of the Russian Federation. 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaia, d. 9
*g.s.maltseva@gmail.com
ФГБУ Санкт-Петербургский НИИ уха, горла, носа и речи Минздрава России. 190013, Россия, Санкт-Петербург, ул. Бронницкая, д. 9
*g.s.maltseva@gmail.com
________________________________________________
Saint Petersburg Institute of ear, nose and throat and speech of the Ministry of Health of the Russian Federation. 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaia, d. 9
*g.s.maltseva@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.